Heparin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029

The International Society on Thrombosis and Hemostasis 2021 report has stated the global incidence rate of venous thromboembolism to be 2 per 1000 persons. The risk factors associated with venous thromboembolism are prolonged hospital stay, cancer chemotherapy, smoking, alcohol consumption and pregnancy. Heparin has excellent plasma protein binding properties. It has been found to be effective in treatment of Parkinson’s disease via the cathepsin-d activity. Heparin being a glycosaminoglycan has been found to reduce inflammation in rheumatoid arthritis and acute pancreatitis.

The report titled heparin market covers product segment including unfragmented heparin, low molecular weight heparin and ultra-low molecular weight heparin. The route of administration comprises subcutaneous and intravenous. Data forecast and market estimation is covered to understand the latest trend in the products and route of administration segment.

Country cross sectional analysis is covered for the major countries enlisted in the 5 major geographical regions:

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe
• Asia Pacific
• China
• Japan
• Rest of Asia Pacific
• Latin America
• Mexico
• Brazil
• Rest of LATAM
• Middle East and Africa
• GCC
• Rest of Middle East and Africa

Market size and data forecast are covered in the geography segment to understand the attractive investment proposition by geography.

Company profiles covers important information such as recent news coverage, business information and product portfolio. Product portfolio gives a clear understanding the recent trend present in the heparin market. Recent news covers the latest launch of value added heparin product and technological development in the production of synthetic heparin. Market assessment and data forecast elucidates the existing business milieu in global heparin market. The ace players involved in the production of heparin are Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA.

Based on product, the global heparin market is categorized into:

• Unfractionated Heparin
• Low Molecular Weight Heparin
• Ultra-Low Molecular Weight Heparin

Heparin is an anticoagulant prescribed for the treatment of venous complications such as arterial thromboembolism, deep vein thrombosis and pulmonary embolism. It is produced by the mast cells and basophils and binds to the enzyme antithrombin III and further causes inactivation of blood clotting factor thrombin. Heparin is produced from the mucosal tissues of slaughtered porcine and bovine. It is present in the World Health Organization list of essential medicines which depicts its importance in the treatment. The low molecular weight represents the largest market share in the products segment due to its enhanced bioavailability and less subcutaneous dosing frequency for complication like venous thromboembolism. Additionally the most important advantage of low molecular weight heparin is reduced risk of heparin induced thrombocytopenia. On the other hand, Ultra-low molecular weight heparin has enhanced safety and efficacy due to its structural configuration promoting depolymerization. Increasing demand as a therapeutic agent providing thromboprophylaxis in cancer patients undergoing surgery drives the medicinal application of ultra-low molecular weight heparin. Top players in heparin market are Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA.

Based on route of administration, the heparin market is categorized into:

• Subcutaneous
• Intravenous

The biological half-life of fragmented heparin is 1-2 hours after infusion and low molecular weight heparin has half-life 4 times more than fragmented heparin. Proper caution needs to be taken while considering the dose specifications of heparin as there are severe side effects of overdose. Protamine sulphate has been useful to a certain extent to reverse the heparin overdose effect but logically it is not possible to determine the blood concentration of heparin owing to its excellent plasma protein binding. Subcutaneous route is the most preferred route owing to its enhanced safety, less administration time and relatively available at lower cost. It is useful in pregnant women having increased risk for venous thromboembolism and patients undergoing reproductive immunology treatment. Intravenous route of administration has advantages such as to fast onset of action and is the most preferred route of choice in open heart surgeries, kidney dialysis and blood transfusion.

For the purpose of this study, the global heparin market is categorized into the following regional and country specific markets:

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Rest of Middle East and Africa

National Center on Birth Defects and Developmental Disabilities has cited that every year in the United States around 900,000 people suffer with venous thromboembolism DVT/PE having a prevalence of 1 to 2 per 1,000 person. Approximately 10% to 30% citizens die after a month of diagnosis and death due to venous thromboembolism is the number one cause in about 25 % of the patients suffering with DVT/PE. North America owns the largest market share in heparin products due to increasing number of patients suffering with DVT/PE and presence of top players actively engaged in the research and development of heparin products. According to European Union statistics the rising prevalence of coagulation disorders results in death of approximately half a million E.U. citizens each year. Additionally the supportive regulatory environment created by European Medical Agency for synthetic heparin products provide thrust to the European heparin market growth. Asia Pacific will register a remarkable growth in heparin products as the patent expiry of low molecular weight heparin will boost the generic market. World Health Organization has stated that the major cause of death in Asia Pacific regarding clotting disorders is pulmonary embolism.


This product will be delivered within 2 business days.